Revelation Biosciences (OTCMKTS:REVB – Get Rating) and Savara (NASDAQ:SVRA – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.
Earnings and Valuation
This table compares Revelation Biosciences and Savara's revenue, earnings per share and valuation.
Get Revelation Biosciences alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Revelation Biosciences | N/A | N/A | -$2.13 million | N/A | N/A |
| Savara | $260,000.00 | 710.56 | -$43.01 million | ($0.25) | -6.48 |
Revelation Biosciences has higher earnings, but lower revenue than Savara.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Revelation Biosciences and Savara, as provided by MarketBeat.com.| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Revelation Biosciences | 0 | 0 | 1 | 0 | 3.00 |
| Savara | 0 | 0 | 1 | 0 | 3.00 |
Revelation Biosciences currently has a consensus target price of $12.00, indicating a potential upside of 5,376.95%. Savara has a consensus target price of $3.00, indicating a potential upside of 85.19%. Given Revelation Biosciences' higher possible upside, equities analysts plainly believe Revelation Biosciences is more favorable than Savara.
Profitability
This table compares Revelation Biosciences and Savara's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Revelation Biosciences | N/A | N/A | -21.61% |
| Savara | N/A | -29.86% | -24.20% |
Insider and Institutional Ownership
5.4% of Revelation Biosciences shares are held by institutional investors. Comparatively, 67.7% of Savara shares are held by institutional investors. 19.9% of Revelation Biosciences shares are held by insiders. Comparatively, 3.6% of Savara shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Risk and Volatility
Revelation Biosciences has a beta of -0.35, meaning that its share price is 135% less volatile than the S&P 500. Comparatively, Savara has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.
Summary
Revelation Biosciences beats Savara on 5 of the 8 factors compared between the two stocks.
About Revelation Biosciences
(Get Rating)
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
About Savara
(Get Rating)
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.